Principal Financial Group
MRSN

Principal Financial Group’s Mersana Therapeutics MRSN Stock Holding History

Principal Financial Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-414
Closed -$3.56K – 2288
2025
Q1 		$3.56K Buy
+414
New +$6.39K ﹤0.01% 2170
2024
Q3 		– Sell
-731
Closed -$36.7K – 2345
2024
Q2 		$36.7K Sell
731
-540
-42% -$39K ﹤0.01% 2308
2024
Q1 		$142K Sell
1,271
-68
-5% -$6.76K ﹤0.01% 2230
2023
Q4 		$77.7K Buy
1,339
+69
+5% +$2.78K ﹤0.01% 2297
2023
Q3 		$40.3K Buy
1,270
+56
+5% +$2.66K ﹤0.01% 2361
2023
Q2 		$99.8K Buy
1,214
+196
+19% +$28.7K ﹤0.01% 2289
2023
Q1 		$105K Buy
1,018
+143
+16% +$20.1K ﹤0.01% 2295
2022
Q4 		$128K Buy
875
+118
+16% +$19.9K ﹤0.01% 2262
2022
Q3 		$128K Buy
757
+199
+36% +$32.3K ﹤0.01% 2284
2022
Q2 		$64K Buy
558
+111
+25% +$10.4K ﹤0.01% 2444
2022
Q1 		$45K Buy
447
+27
+6% +$3.15K ﹤0.01% 2490
2021
Q4 		$65K Sell
420
-621
-60% -$121K ﹤0.01% 2470
2021
Q3 		$245K Sell
1,041
-1
-0.1% -$292 ﹤0.01% 2375
2021
Q2 		$353K Sell
1,042
-2,204
-68% -$834K ﹤0.01% 2305
2021
Q1 		$1.31M Buy
3,246
+135
+4% +$65.5K ﹤0.01% 1936
2020
Q4 		$2.07M Buy
+3,111
New +$1.73M ﹤0.01% 1790

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Principal Financial Group's MRSN Position: Q2 2025 in Review

Principal Financial Group sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 414 shares — an estimated $3.56K sold.

Principal Financial Group first reported a position in MRSN in Q4 2020 and held it in 16 quarters. The position peaked at $2.07M in Q4 2020. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • Principal Financial Group reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Principal Financial Group sold 414 Mersana Therapeutics shares in Q2 2025, an estimated $3.56K.
  • Principal Financial Group first reported a position in Mersana Therapeutics in Q4 2020 and held it in 16 quarters.
  • Principal Financial Group's Mersana Therapeutics position peaked at $2.07M in Q4 2020.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on Principal Financial Group's 13F filing for Q2 2025, filed 8 Aug 2025.